Chronic elevation of plasma fibroblast growth factor 19 in long-term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern?

Hepatology. 2018 Feb;67(2):782-784. doi: 10.1002/hep.29511. Epub 2017 Dec 26.

Authors

Frank G Schaap^{1

2}, Peter L M Jansen¹, Steven W M Olde Damink^{1

2}

Affiliations

¹ Department of Surgery, Maastricht University NUTRIM School of Nutrition and Translational Research in Metabolism Maastricht University, Maastricht, The Netherlands.
² Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.

PMID: 28865148
DOI: 10.1002/hep.29511

No abstract available

MeSH terms

Animals
Carcinoma, Hepatocellular / etiology*
Fibroblast Growth Factors / blood*
Fibroblast Growth Factors / genetics
Fibroblast Growth Factors / physiology
Humans
Liver Neoplasms / etiology*
Mice
Non-alcoholic Fatty Liver Disease / complications
Non-alcoholic Fatty Liver Disease / drug therapy*
Receptors, Cytoplasmic and Nuclear / agonists*

Substances

FGF19 protein, human
Receptors, Cytoplasmic and Nuclear
farnesoid X-activated receptor
Fibroblast Growth Factors